Karyopharm: Anders Hove reports 5.7% ownership

The reported ownership percentages use 22,681,460 Karyopharm shares outstanding as of June 30, 2026.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. is named as the issuer in an amended Schedule 13G reporting beneficial ownership by Acorn Bioventures, L.P. (539,373 shares; 2.4%), Acorn Bioventures 2, L.P. (744,848 shares; 3.3%), and Anders Hove (1,284,221 shares; 5.7%). The two general partners are also listed at their respective fund’s share amount, and Hove is identified as manager of both. The percentages are based on 22,681,460 shares outstanding as of June 30, 2026.

Key Figures

Beneficial ownership — Acorn Bioventures, L.P.: 539,373 shares (2.4%) Beneficial ownership — Acorn Bioventures 2, L.P.: 744,848 shares (3.3%) Beneficial ownership — Anders Hove: 1,284,221 shares (5.7%) +1 more

4 metrics

Beneficial ownership — Acorn Bioventures, L.P. 539,373 shares (2.4%) Amended Schedule 13G

Beneficial ownership — Acorn Bioventures 2, L.P. 744,848 shares (3.3%) Amended Schedule 13G

Beneficial ownership — Anders Hove 1,284,221 shares (5.7%) Amended Schedule 13G

Common Stock outstanding 22,681,460 shares As of June 30, 2026; basis for reported ownership percentages

Key Terms

beneficial ownership, Shared Voting Power, Shared Dispositive Power

3 terms

beneficial ownership regulatory

"Amount beneficially owned"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Shared Voting Power regulatory

"Shared Voting Power 539,373.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Shared Dispositive Power regulatory

"Shared Dispositive Power 539,373.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KPTI shares does Anders Hove report beneficially owning?

The report lists Anders Hove with beneficial ownership of 1,284,221 shares, or 5.7%. It says he may be deemed to beneficially own shares held by both general partners.

What KPTI holdings are reported for the Acorn Bioventures funds?

Acorn Bioventures, L.P. is listed with 539,373 shares (2.4%), and Acorn Bioventures 2, L.P. with 744,848 shares (3.3%). Their respective general partners are listed with the same share amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 02:19 PM Accepted by SEC EDGAR 09/25/2026 - 02:18 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

48576U205

(CUSIP Number)

09/22/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN BIOVENTURES, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 539,373.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 539,373.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

539,373.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN CAPITAL ADVISORS GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 539,373.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 539,373.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

539,373.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

ACORN BIOVENTURES 2, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 744,848.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 744,848.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

744,848.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Acorn Capital Advisors GP 2, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 744,848.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 744,848.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

744,848.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Anders Hove

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,284,221.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,284,221.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,284,221.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Karyopharm Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 85 WELLS AVENUE, NEWTON, MASSACHUSETTS, 02459.
Item 2.
(a)	Name of person filing: Acorn Bioventures, L.P. Acorn Capital Advisors GP, LLC Acorn Bioventures 2, L.P. Acorn Capital Advisors GP2, LLC Anders Hove
(b)	Address or principal business office or, if none, residence: 420 Lexington Avenue, Suite 2626, New York, New York 10170
(c)	Citizenship: Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 Par Value
(e)	CUSIP No.: 48576U205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
(b)	Percent of class: The percentages set forth herein are calculated based upon 22,681,460 shares of Common Stock outstanding as of June 30, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 13, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, L.P. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.
	(ii) Shared power to vote or to direct the vote: Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
	(iii) Sole power to dispose or to direct the disposition of: NA
	(iv) Shared power to dispose or to direct the disposition of: NA
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ACORN BIOVENTURES, L.P.

Signature:	Anders Hove
Name/Title:	Manager of General Partner
Date:	09/25/2026

ACORN CAPITAL ADVISORS GP, LLC

Signature:	Anders Hove
Name/Title:	Manager
Date:	09/25/2026

ACORN BIOVENTURES 2, L.P.

Signature:	Anders Hove
Name/Title:	Manager of General Partner
Date:	09/25/2026

Acorn Capital Advisors GP 2, LLC

Signature:	Anders Hove
Name/Title:	Manager
Date:	09/25/2026

Anders Hove

Signature:	Anders Hove
Name/Title:	Individually
Date:	09/25/2026